CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 23 enrolled
Drug / intervention
Carboplatin +1 moredrug
Likely dose
Paclitaxel 175 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00502203
NCT00502203Phase 2Completed
CompareCT.gov

A Phase II Multicenter Trial of Paclitaxel and Carboplatin in Women With Advanced (IIIb, IIIc, IVa and IVb) or Recurrent (All Stages) Malignant Mixed Mullerian Tumors (MMMT) of the Uterus

M.D. Anderson Cancer Center·interventional·Posted Jul 17, 2007·Updated May 9, 2016

In Brief

A Phase 2 clinical trial evaluating Carboplatin and Paclitaxel for Mixed Tumor, Mullerian. Completed, enrolled 23 participants across 4 sites.

Detailed Summary

The goal of this clinical research study is to find out if the combination of paclitaxel and carboplatin chemotherapy can shrink or slow the growth of mixed mullerian tumors (MMMT) of the uterus.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMixed Tumor, Mullerian
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 17, 2007
Enrollment StartAug 1, 2001
Primary CompletionNov 1, 2010
TodayJul 2, 2026
Enrollment to primary: 9.3 yearsPosted 19.0 years ago

Interventions

Carboplatindrug

AUC 5 By Vein Over 1 Hour Every 21 Days for 6 Courses

Paclitaxeldrug

175 mg/m\^2 By Vein Over 3 Hours Every 21 Days for 6 Courses